Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 931-670-0 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Study period:
- 1979-04-03 - 1980-03-31
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: - study compliant to OECD 401 - non-GLP
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 980
- Report date:
- 1980
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- Principles of method if other than guideline:
- the study was conducted to compare the sensitivity of Sprague Dawley rats and CDF rats (F-344 derived) against 6 different substance including 3-chloropropene
- GLP compliance:
- no
- Test type:
- standard acute method
- Limit test:
- no
Test material
Reference
- Name:
- Unnamed
- Type:
- Constituent
- Details on test material:
- - Name of test material (as cited in study report): allyl chloride
- Substance type: short chain chlorinated hydrocarbon
- Physical state: not reported
- Analytical purity: 98.6% 3-chloropropene
- Impurities (identity and concentrations): ; 0.74% isopropyl chloride; 0.40% 1,5-hexadiene; 0.14% normal propyl chloride; 0.10% 2,2- dichloropropane
- Purity test date: not reported
- Lot/batch No.: TB 06308-3
- Expiration date of the lot/batch: not reported
- Stability under test conditions: not reported, but expected to be stable
- Storage condition of test material: not reported
Test animals
- Species:
- rat
- Strain:
- other: Sprague Dawley rats and CDF rats (F-344 derived)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Spb: (Sprague-Dawley) rats (Spartan Research Animals, Inc., Haslett, Michigan)
CDF (Fischer 344-derived) rats (Charles River Breeding Laboratories, Inc., Portage, Michigan)
- Age at study initiation: 7-8 wks
- Weight at study initiation (averages): Sprague Dawley males: 308 g, Sprague Dawley females: 192 g, CDF males: 136 g, CDF females 88 g,
- Fasting period before study: 16-18 hours prior to dosing
- Housing: 2 or 3/cage
- Diet (e.g. ad libitum): commercial laboratory chow (Ralston Purina Company, St. Louis, Missouri), probably ad libitum
- Water (e.g. ad libitum): water, ad libitum
- Acclimation period: >= 1 wk
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22.8
- Humidity (%): 45
- Air changes (per hr): not reported
- Photoperiod (hrs dark / hrs light): 12/12
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- unchanged (no vehicle)
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: not applicable, no vehicle used
MAXIMUM DOSE VOLUME APPLIED: 1580 mg/Kg bw
- Doses:
- all doses in mg/Kg bw
Male Sprague-Dawley Rat: 200, 398, 795, 1580
Female Sprague-Dawley Rat: 200, 398, 795, 1580
Male CDF Rat: 200, 398, 795, 1580
Female CDF Rat: 63, 126, 200, 398, 795, 1580 - No. of animals per sex per dose:
- 5 rats/sex/strain
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: observed each working day during the observation period; weighed immediately prior to treatment, and weekly thereafter
- Necropsy of survivors performed: yes
- Other examinations performed: no - Statistics:
- The acute oral median lethal dose, 95% confidence interval, and approximate slope of the dose-response curve for both strains for all test articles were calculated by the moving average method of Thompson and Weil (Thompson, W. R. and C. S. Weil, Biometrics, Vol. 8, No. 1, March, 1952, pp. 51-54. As implemented in a computer program (Stephan, C., 1978, personal communication)), as implemented by a computer program (Stephan, 1978).
The approximate slope was calculated as 1/2 1og10 (LD84/LD16). Because this computer program also computes LD5O's, 95% confidence intervals, and slopes by probit analysis (Finney, D. J. (1972) Probit Analysis. Third Edition, Cambridge University Press, Cambridge, England.), the values obtained from both methods of analysis are reported to assess the comparability of the 2 procedures.
Results and discussion
Effect levelsopen allclose all
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- 275 mg/kg bw
- 95% CL:
- 180 - 526
- Remarks on result:
- other: CDF rats, moving average method
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- 293 mg/kg bw
- 95% CL:
- 177 - 719
- Remarks on result:
- other: CDF rats, probit analysis
- Sex:
- male
- Dose descriptor:
- LD50
- Effect level:
- 419 mg/kg bw
- 95% CL:
- 298 - 612
- Remarks on result:
- other: CDF rats, moving average method
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- 455 mg/kg bw
- 95% CL:
- 260 - 685
- Remarks on result:
- other: Sprague Dawley rats, moving average method
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- 435 mg/kg bw
- 95% CL:
- 241 - 751
- Remarks on result:
- other: Sprague Dawley rats, probit analysis
- Sex:
- male
- Dose descriptor:
- LD50
- Effect level:
- 379 mg/kg bw
- 95% CL:
- 259 - 533
- Remarks on result:
- other: Sprague Dawley rats, moving average method
- Mortality:
- see table 1
- Clinical signs:
- Clinical signs comprised slight to extreme lethargy, diarrhea, piloerection and convulsions (1 male and one female of the 795 mg/kg group).
The no. and severity of clinical signs rose dose dependently.
See table 2 for details - Body weight:
- no clear dose dependent effect could be stated due to the high mortality in the two high dose groups
- Gross pathology:
- The following lesions were found:
general: focal corneal cloudiness and accumulation of exudate around eyes
Lungs: Multiple pinpoint gray foci scattered throughout all lobes
Stomach: Thickening and roughening of nonglandular squamous epithelium, focal thickening of nonglandular stomach wall, erosion of nonglandular epithelium, firm, nodular-like foci throughout epithelial surface, perforated ulcer and fibrous adhesions between stomach and liver, spleen, or diaphragm
for details, see table 4
Any other information on results incl. tables
- Table 1: Mortality (no. of dead/no. of treated)
Dose (mg/kg) |
Male Sprague-Dawley |
Female Sprague-Dawley |
Male CDF |
Female CDF |
63 |
|
|
|
0/5 |
126 |
|
|
|
3/10 |
200 |
0/5 |
0/5 |
0/5 |
1/5 |
398 |
3/5 |
3/5 |
2/5 |
2/5 |
795 |
5/5 |
4/5 |
5/5 |
5/5 |
1580 |
5/5 |
5/5 |
5/5 |
5/5 |
- Table 2: Clinical signs
Dose (mg/kg) |
Signs of Toxicity |
Male Sprague-Dawley |
Female Sprague-Dawley |
Male CDF |
Female CDF |
63 |
Slight lethargy |
- |
|
- |
5/5 |
126 |
Slight lethargy |
|
|
- |
10/10 |
200 |
Lethargy |
5/5 |
5/5 |
5/5 |
5/5 |
Piloerection |
0/5 |
0/5 |
5/5 |
5/5 |
|
398 |
Lethargy |
5/5 |
5/5 |
5/5 |
5/5 |
Diarrhea |
3/5 |
3/5 |
2/5 |
2/5 |
|
Piloerection |
0/5 |
5/5 |
5/5 |
5/5 |
|
795 |
Extreme lethargy |
5/5 |
5/5 |
5/5 |
5/5 |
Diarrhea |
5/5 |
4/5 |
5/5 |
5/5 |
|
Piloerection |
0/5 |
0/5 |
0/5 |
0/5 |
|
Convulsions |
0/5 |
0/5 |
1/5 |
1/5 |
|
1580 |
Extreme lethargy |
5/5 |
5/5 |
5/5 |
5/5 |
Severe diarrhea |
5/5 |
5/5 |
5/5 |
5/5 |
- Table 3: body weight development
Dose (mg/kg) |
Male |
Female |
Male CDF |
Female CDF |
||||||||||||
n |
Initial Weight (g) |
n |
Final Weight (g) |
n |
Initial Weight (q) |
n |
Final Weight (g) |
n |
Initial Weight (q) |
n |
Final Weight (g) |
n |
Initial Weight (g) |
n |
Final Weight (gl‑ |
|
63 |
|
|
|
|
- |
|
- |
|
|
|
|
|
5 |
82±5 |
5 |
133±2 |
126 |
|
|
- |
|
|
|
- |
|
|
|
- |
|
5 |
83±5 |
3 |
133±9 |
200 |
5 |
308±13 |
5 |
403±22 |
5 |
193±6 |
5 |
236±8 |
5 |
139±7 |
5 |
214±7 |
5 |
92±1 |
4 |
143±7 |
398 |
5 |
296±12 |
2 |
284±10 |
5 |
191±3 |
2 |
238±6 |
5 |
135±7 |
3 |
136±9 |
5 |
91±4 |
3 |
143±3 |
795 |
5 |
308±8 |
a |
|
5 |
189±4 |
1 |
250 |
5 |
136.2±6 |
a |
|
5 |
94±2 |
a |
|
1580 |
5 |
318±13 |
a |
|
5 |
196±12 |
|
|
5 |
135±6 |
a |
|
5 |
88±4 |
a |
|
a: No survivors
- Table 4: Results of gross necroscopy (no. of affected/no. of examined)
Gross Observations |
63 |
126 |
200 |
398 |
||||||
Female CDF |
Female CDF |
Male |
Female S.D. |
Male CDF |
Female CDF |
Male |
Female S.D. |
Male COF |
Female CDF |
|
General |
||||||||||
No visible lesion |
2/5 |
1/7 |
0/5 |
0/5 |
1/5 |
3/4 |
0/2 |
0/3 |
0/3 |
1/3 |
Focal corneal cloudiness |
3/5 |
0/7 |
0/5 |
0/5 |
1/5 |
0/4 |
0/2 |
1/3 |
1/3 |
0/3 |
Accumulation of exudate around eyes |
0/5 |
0/7 |
0/5 |
0/5 |
0/5 |
0/4 |
1/2 |
0/3 |
1/3 |
0/3 |
Respiratory System |
||||||||||
Lungs |
|
|
|
|
|
|
|
|
|
|
Multiple pinpoint gray foci scattered throughout all lobes |
0/5 |
0/7 |
0/5 |
1/5 |
0/5 |
0/4 |
0/2 |
0/3 |
0/3 |
0/3 |
Gastrointestinal System |
||||||||||
Stomach |
|
|
|
|
|
|
|
|
|
|
Thickening and roughening of nonglandular squamous epithelium |
0/5 |
5/7 |
5/5 |
5/5 |
4/5 |
1/4 |
1/2 |
2/3 |
3/3 |
2/3 |
Focal thickening of nonglandular stomach wall |
0/5 |
0/7 |
1/5 |
3/5 |
.0/5 |
0/4 |
0/2 |
0/3 |
0/3 |
0/3 |
Erosion of nonglandular epithelium |
0/5 |
0/7 |
0/5 |
0/5 |
0/5 |
0/4 |
1/2 |
2/3 |
2/3 |
0/3 |
Firm, nodular-like foci throughout epithelial surface |
0/5 |
0/7 |
0/5 |
0/5 |
0/5 |
0/4 |
0/2 |
0/3 |
1/3 |
0/3 |
Perforated Ulcer |
0/5 |
0/7 |
0/5 |
0/5 |
0/5 |
0/4 |
0/2 |
1/3 |
0/3 |
0/3 |
Fibrous adhesions between stomach and liver, spleen, or diaphragm |
0/5 |
0/7 |
0/5 |
0/5 |
0/5 |
0/4 |
1/2 |
2/3 |
1/3 |
0/3 |
no survivors at higher dose levels
Applicant's summary and conclusion
- Interpretation of results:
- Category 3 based on GHS criteria
- Remarks:
- Migrated information
- Executive summary:
The present study was conducted in compliance to the OECD guideline 401. Male and female Sprague Dawley rats and CDF rats (F-344 derived) were treated once with 3 -chloropropene via gavage without vehicle observed for clinical signs, weight development and overt signs of toxicity for 14 d post administration (dosage in mg/Kg bw: 200, 398, 795, 1580, female CDF also 63 and 126). Survivors were sacrificed and subjected to gross necroscopy.
The most critical derived LD50 value was 275 mg/kg bw (180 — 526, 95 % CL) for female CDF rats. Based on the determined LD50 values the substance has to be classified as Category III (Danger, toxic if swallowed) according to CLP as implementation of UN GHS in the EU (REGULATION (EC) No 1272/2008 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL).
Clinical signs comprised slight to extreme lethargy, diarrhea, piloerection and convulsions (1 male and one female of the 795 mg/kg group). The no. and severity of clinical signs rised dose dependently.
No clear dose dependent body weight effect could be stated due to the high mortality in the two high dose groups.
At terminal necroscopy of survivors focal corneal cloudiness and accumulation of exudate around eyes were found. Lungs exhibited multiple pinpoint gray foci scattered throughout all lobes. In the stomach thickening and roughening of nonglandular squamous epithelium, focal thickening of nonglandular stomach wall, erosion of nonglandular epithelium, firm, nodular-like foci throughout epithelial surface and perforated ulcers were found. In addition fibrous adhesions between stomach and liver, spleen, or diaphragm were seen. The severity of these findings increased generally dose dependently.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.